Keybanc Maintains Overweight on ResMed, Lowers Price Target to $290
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $302 to $290.
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $302 to $290.